Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/95226
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Pharmacogenetics of opioid response |
Author: | Somogyi, A. Coller, J. Barratt, D. |
Citation: | Clinical Pharmacology and Therapeutics, 2015; 97(2):125-127 |
Publisher: | Wiley |
Issue Date: | 2015 |
ISSN: | 0009-9236 1532-6535 |
Statement of Responsibility: | AA Somogyi, JK Coller and DT Barratt |
Abstract: | For opioids requiring CYP2D6 O-demethylation to active metabolites, poor metabolizers have reduced metabolite formation and minimal pain reduction. Clinically, this has only reliably been shown for tramadol. Ultra-rapid metabolizers have an increased risk of toxicity especially for codeine. ABCB1 genetics show no consistent findings. In Asian populations, the high OPRM1 118A>G frequency associates with higher opioid dosage requirements. Clinical translation of opioid genetics is premature because many important pain and addiction phenotype factors contribute. |
Keywords: | Humans Pain Cytochrome P-450 Enzyme System Glucuronosyltransferase Analgesics, Opioid |
Rights: | © 2014 American Society for Clinical Pharmacology and Therapeutics |
DOI: | 10.1002/cpt.23 |
Published version: | http://dx.doi.org/10.1002/cpt.23 |
Appears in Collections: | Aurora harvest 3 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.